Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.60 |
| ▸ | AKT2 | P31751 | 12/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 3/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.57 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7851067 | 0.94 | HTR2C (0.62) | JAK3AKT2GSK3BKITHTR2C | |
| SCHEMBL3952915 | 0.82 | JAK3 (0.67) | JAK3AKT2GSK3BKITHTR2C | |
| SCHEMBL27776221 | 0.79 | AKT2 (0.49) | JAK3AKT2GSK3BKITHTR2C | |
| SCHEMBL2019605 | 0.79 | JAK3 (0.70) | JAK3AKT2GSK3BKITHTR2C | |
| SCHEMBL1789204 | 0.79 | RPS6KB1 (0.72) | JAK3AKT2GSK3BKITHTR2C | |
| SCHEMBL2780797 | 0.79 | AKT2 (0.67) | JAK3AKT2AKT1ROCK2AKT3 | |
| SCHEMBL3953923 | 0.77 | JAK3 (0.61) | JAK3AKT2GSK3BHTR2CLCK | |
| SCHEMBL2781969 | 0.77 | AKT2 (0.66) | JAK3AKT2GSK3B | |
| SCHEMBL7858238 | 0.77 | HTR2C (0.67) | JAK3AKT2GSK3BKITHTR2C | |
| SCHEMBL10156821 | 0.77 | JAK3 (0.59) | JAK3AKT2GSK3BKITHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| CN-105106199-A | Methods of using MEK inhibitors | EXELIXIS INC | 2015-12-02 | — | — | CN | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| CN-101605540-A | Methods of using MEK inhibitors | EXELIXIS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| CN-1125070-C | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2003-10-22 | — | — | CN | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| CN-1305479-A | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | JAK3 2/4885AKT2 731/4885GSK3B 666/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | JAK3 81/4885AKT2 130/4885GSK3B 546/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | JAK3 173/4885AKT2 7/4885GSK3B 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.